Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease
Year: 2022
Type: article
Source: Neurology
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Keywords: aducanumab, Alzheimer's disease, cost-effectiveness, value-based pricing, drug pricing, incremental cost-effectiveness ratio, quality-adjusted life years, Markov model, societal perspective, threshold analysis, early Alzheimer's disease, accelerated approval, supportive care, health technology assessment, drug reimbursement decision-making
Open Access status: closed
OpenAlex ID: W4205869346
